reports
- Guy Sips
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Vranken
- Wim Hoste
MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpo...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced that the exploratory single-arm, open-label Phase 1b clinical trial named IASO () evaluating MaaT033 in ALS has met its primary endpoint assessing the safety and tolerability of MaaT033 with multiple doses. The independent Data Safety and Monitoring Board (DSMB) concluded that MaaT033 showed good safety an...
MaaT Pharma annonce des résultats positifs de Phase 1b, avec l’atteint...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers grâce à la modulation du système immunitaire, annonce que l'essai clinique exploratoire de Phase 1b à bras unique et ouvert nommé IASO () évaluant MaaT033 dans la SLA a atteint son critère principal d'évaluation portant sur la sécurité et la tolérabilité de doses multiples de MaaT033. Le comité indépendant de surveillance e...
- Jerôme Bodin
ALLIX WALLIX GROUP SA
APAML APERAM SA
DEC JCDECAUX SA
NRG NRJ GROUP SA
GOE GROUPE GORGE SA
ALTA ALTAREA SCA
BAMNB KONINKLIJKE BAM GROEP NV
BON BONDUELLE SCA
ADV ADVA AG OPTICAL NETWORKING
AALB AALBERTS N.V.
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
VGP VGP NV
SIFG SIF HOLDING NV
FNTN FREENET AG
ALFEN ALFEN NV
COP COMPUGROUP MEDICAL SE & CO. KGAA
TCH TECHNICOLOR SA
ECMPA EUROCOMMERCIAL PROPERTIES NV
IVG IVECO GROUP
FLE PEGASUS ENTREPRENEURIAL ACQUISITION CO EURO BV
BRE BREMBO S.P.A.
- Jerôme Bodin
ALLIX WALLIX GROUP SA
APAML APERAM SA
DEC JCDECAUX SA
NRG NRJ GROUP SA
LNA LNA SANTE SA
GOE GROUPE GORGE SA
ALTA ALTAREA SCA
BAMNB KONINKLIJKE BAM GROEP NV
BON BONDUELLE SCA
ADV ADVA AG OPTICAL NETWORKING
AALB AALBERTS N.V.
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
VGP VGP NV
SIFG SIF HOLDING NV
FNTN FREENET AG
ALFEN ALFEN NV
COP COMPUGROUP MEDICAL SE & CO. KGAA
TCH TECHNICOLOR SA
ECMPA EUROCOMMERCIAL PROPERTIES NV
IVG IVECO GROUP
FLE PEGASUS ENTREPRENEURIAL ACQUISITION CO EURO BV
BRE BREMBO S.P.A.
- Thijs Berkelder
Alfen : Smart Grids under control, but tough charging equipment market...
>Feedback analyst conference call - Alfen’s analyst call was hosted by CEO Marco Roeleveld, CCO Michele Lesh and CFO Onno Krab. Key topics were the following:Outlook per sector:- Smart Grid Solutions, substation production is to increase to c. 100 per week in Q4, but in H1 2025 will drop back to 70 per week because of customer constraints. Hopes H2 2025 to be able to up production further, but dependent on clients. Key clients are the grid operators as small...
- Thijs Berkelder
Alfen : Smart Grids under control, but tough charging equipment market...
>Feedback analyst conference call - Alfen’s analyst call was hosted by CEO Marco Roeleveld, CCO Michele Lesh and CFO Onno Krab. Key topics were the following:Outlook per sector:- Smart Grid Solutions, substation production is to increase to c. 100 per week in Q4, but in H1 2025 will drop back to 70 per week because of customer constraints. Hopes H2 2025 to be able to up production further, but dependent on clients. Key clients are the grid operators as small...
- Emira Sagaama
- Juan Ros-Padilla
AMS AMS AG
CRI CHARGEURS SA
EVT EVOTEC SE
FLY SOCIETE FONCIERE LYONNAISE SA
LXS LANXESS AG
BEN BENETEAU SA
KCO KLOECKNER & CO SE
VLS VALNEVA SE
JCQ JACQUET METALS SA
ELG ELMOS SEMICONDUCTOR SE
BAMNB KONINKLIJKE BAM GROEP NV
WIZZ WIZZ AIR HOLDINGS PLC
GN GN STORE NORD A/S
GLB GLANBIA PLC
DEZ DEUTZ AG
AALB AALBERTS N.V.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
FDR FLUIDRA S.A.
CPINV CARE PROPERTY INVEST SA
LOG COMPANIA DE DISTRIBUCION INTEGRAL LOGISTA HOLDINGS S.A.
TWEKA TKH GROUP N.V. CERT
SMHN SUESS MICROTEC AG
DIC DIC ASSET AG
ALFEN ALFEN NV
INS INSTONE REAL ESTATE GROUP AG
HAG HENSOLDT AG
COP COMPUGROUP MEDICAL SE & CO. KGAA
KTA KNAUS TABBERT
RWI RENEWI PLC
HGEA HGEARS AG
AF AIR FRANCE - KLM
- Emira Sagaama
- Juan Ros-Padilla
AMS AMS AG
CRI CHARGEURS SA
EVT EVOTEC SE
FLY SOCIETE FONCIERE LYONNAISE SA
LXS LANXESS AG
BEN BENETEAU SA
KCO KLOECKNER & CO SE
VLS VALNEVA SE
JCQ JACQUET METALS SA
ELG ELMOS SEMICONDUCTOR SE
BAMNB KONINKLIJKE BAM GROEP NV
WIZZ WIZZ AIR HOLDINGS PLC
GN GN STORE NORD A/S
GLB GLANBIA PLC
DEZ DEUTZ AG
AALB AALBERTS N.V.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
FDR FLUIDRA S.A.
CPINV CARE PROPERTY INVEST SA
LOG COMPANIA DE DISTRIBUCION INTEGRAL LOGISTA HOLDINGS S.A.
TWEKA TKH GROUP N.V. CERT
SMHN SUESS MICROTEC AG
DIC DIC ASSET AG
ALFEN ALFEN NV
INS INSTONE REAL ESTATE GROUP AG
HAG HENSOLDT AG
COP COMPUGROUP MEDICAL SE & CO. KGAA
KTA KNAUS TABBERT
RWI RENEWI PLC
HGEA HGEARS AG
AF AIR FRANCE - KLM
- ING Helpdesk
Benelux Morning Notes
Aalberts: Building already bottoming, industry tough. Air France-KLM: Nobody helps. Alfen: Covenant agreement, hikes output Smart Grid. AMG: Sweet for 2024F, sour for 2025F. ArcelorMittal: 3Q24 EBITDA beats by 6%, FCF solid. BAM: 3Q beats, on its way to reach FY guidance. CMB.TECH: 3Q and FY24 reasonable but then more challenges. D'Ieteren: EGM and dividend dates announced; Belron US peer Boyd disappointing 3Q24. GBL: Double-digit TSR expected over 2024-27F. KBC: 3Q better acro...
- Mahaut Arnaud
- Paul de Froment
- Thomas Mordelle
Alfen: Q3 results, big Q4 ahead
Alfen published Q3 2024 figures yesterday. Revenue came in at EUR106m (-18% QoQ vs. EUR129m in Q2 2024, -22% YoY vs. EUR136m in Q3 2023) pointing to EUR352m YTD (vs. cons. eyeing EUR489m for FY24). Q3 numbers were mostly impacted by modest revenue growth in Smart Grids (+1% YoY) and a sluggish pace
- Thijs Berkelder
Alfen : Outlook for Q4 and 2025 seems weaker than before
>Q3 better than consensus FY24 outlook slightly weaker = weaker Q4 - Revenues in-line, with strength in Smart Grids offsetting weakness in EV Charging. Revenues in 24Q3 were down 22% y-o-y to € 106.2m (1% below consensus of € 107.4m) with Smart Grid Solutions up 1% to € 50.3m (14% above consensus of € 44.3m), EV Charging Equipment down 6% to € 32.9m (14% below consensus of € 38.3m), and Energy Storage Systems down 55% to € 23.1m (consensus € 23.5m). Profitabil...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
MaaT Pharma présentera une mise à jour des données issues de son progr...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers grâce à la modulation du système immunitaire, annonce que les données mises à jour issues du programme d'accès compassionnel (Early Access Program ou EAP) en Europe portant sur 154 patients atteints de la maladie du greffon contre l’hôte gastro-intestinale (GI-aGvH) réfractaire aux stéroïdes (SR) ou dépendante aux stéroïdes ...
MaaT Pharma to Present Updates from Early Access Program at the 2024 A...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced that updated results from its Early Access Program of MaaT013 in 154 patients with steroid-refractory (SR) or dependent (SD) gastrointestinal acute Graft-versus-Host Disease (GI-aGvHD) have been selected for poster presentation at the . GI-aGvHD is a major cause of morbidity and mortality following allogene...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
ASH abstracts Autolus, Galapagos, MaaT
The abstracts for presentations at ASH (7-10 December) became available yesterday during the day (here). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (digging deeper into the obe-cel dataset), Galapagos (more CAR-T data and pre-clinical data on TCR-T) and MaaT (early access program in aGvHD):
MaaT Pharma publie ses résultats financiers pour le troisième trimestr...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers grâce à la modulation du système immunitaire, annonce aujourd'hui un point sur ses activités et la publication de sa trésorerie et de son chiffre d’affaires jusqu'au 30 septembre 2024. Faits cliniques marquants MaaT013 Hémato-oncologie : En , MaaT Pharma a annoncé que les lots de MaaT013 étaient produits et prêts à êtr...
MaaT Pharma Provides Third Quarter 2024 Business and Financial Results...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today provided a business update and reported its cash position and revenue as of September 30, 2024. Pipeline highlights MaaT013 In hemato-oncology: In , MaaT Pharma announced that MaaT013 batches were ready for distribution for clinical supply in the US and that MaaT Pharma advanced the readiness phase for th...
- ING Helpdesk
Benelux Morning Notes
Alfen: Preview – expect 3Q to be light compared to 4Q. BAM: Preview - it doesn't feel that good. Brunel International: 3Q24 results: 4% EBIT miss – weak outlook. Fugro: Unexpected sales decline in US and Middle East. Kinepolis: US Peer Cinemark 3Q24 results beat on strong spending. Universal Music Group: 3Q24 reasonable, 2H24 €400m M&A cash out will hurt
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.